Princess Chulabhorn donates 690,000 cancer drug tablets to patients across Thailand
Princess Chulabhorn donated 690,000 tablets of Imcranib 100, Thailand's first domestically developed targeted cancer drug, to the National Health Security Office for distribution to patients nationwide under the universal healthcare scheme.
Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana on Thursday bestowed 690,000 tablets of a targeted cancer drug to Thailand's National Health Security Office (NHSO) for distribution to cancer patients nationwide under the universal healthcare scheme.
The royal initiative, titled the '69th Birthday Anniversary Cancer Drug Project', was launched in honour of the Princess's upcoming birthday on 4 July 2026. The handover ceremony took place at the Chulabhorn Royal Academy in Bangkok's Lak Si district.
NHSO Secretary-General Dr. Jadej Thammatacharee received the targeted cancer medication, Imcranib 100, which will be distributed to eligible patients under the gold card healthcare scheme across the country.
Imcranib 100 is the first targeted cancer drug developed and manufactured in Thailand by the Chulabhorn Royal Academy's pharmaceutical plant. The drug received approval from Thailand's Food and Drug Administration on 20 May 2025 and was added to the Thai Innovation List on 30 March 2026.
The medication works by inhibiting tyrosine kinase enzymes involved in certain cancers and is considered part of modern targeted cancer therapy, to be prescribed under specialist supervision.
The NHSO said the donated medication would be allocated according to medical guidelines to ensure fair and appropriate access for patients in need.
Officals said the initiative not only expands access to cancer treatment, but also marks a significant step in strengthening Thailand's domestic pharmaceutical capability and long-term medical innovation development.
